Indication

Cardiovascular disease associated with type 2 diabetes mellitus

Cardiovascular disease associated with type 2 diabetes mellitus encompasses a spectrum of macrovascular and myocardial disorders—including coronary artery disease, stroke, peripheral artery disease, diabetic cardiomyopathy, and heart failure—occurring in individuals with type 2 diabetes mellitus. Read more about Cardiovascular disease associated with type 2 diabetes mellitus

30 drugs 26 manufacturers

Advertisement

Drugs that treat it

Common Cardiovascular disease associated with type 2 diabetes mellitus therapies.

Showing 19–27 of 30 drugs

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
ASCEND LABORATO

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
LUPIN PHARMACEU

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
CIPLA USA, INC.

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
ZYDUS PHARMACEU

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
FLORIDA PHARMAC

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
NOVADOZ PHARMAC

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
SANDOZ

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
TEVA PHARM

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
BIOCON PHARMA I
Filter & compare in the drug finder →Opens the drug finder with Cardiovascular disease associated with type 2 diabetes mellitus preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Cardiovascular disease associated with type 2 diabetes mellitus.

Cardiovascular disease associated with type 2 diabetes mellitus encompasses a spectrum of macrovascular and myocardial disorders—including coronary artery disease, stroke, peripheral artery disease, diabetic cardiomyopathy, and heart failure—occurring in individuals with type 2 diabetes mellitus.

This clinical state reflects accelerated vascular and cardiac pathology driven by the interplay of chronic hyperglycemia, systemic insulin resistance, atherogenic dyslipidemia, low-grade systemic inflammation, and oxidative stress.

Pathophysiologically, these metabolic derangements cause extensive endothelial dysfunction, arterial stiffness, plaque destabilization, and myocardial remodeling, dramatically compounding the risk of adverse cardiovascular morbidity and mortality compared to the non-diabetic population.

Personalize your experience

Follow Cardiovascular disease associated with type 2 diabetes mellitus and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it